In the year 2014, Pemetrexed injection Alimta received approval from the FDA along with cisplatin for the initial treatment of patients with malignant mesothelioma. Alimta in combination with cisplatin received approval as the initial chemotherapy treatment in 2008.
This treatment was for metastatic or locally advanced NSCLC for the patients with nonsquamous histology. In 2009, ALIMTA was sanctioned as maintenance therapy for metastatic or locally advanced nonsquamous NSCLC.
The approval and launch of generic economic Pemetrexed in the market and it will expectedly increase its adoption.
Alimta is Eli Lilly and Company’s one of the patented drug, and it is protected by the vitamin regimen patent (2021), and also pediatric exclusivity (2022) in the United States. It is also protected with vitamin regiment patent (2021) in top European countries. In Japan, the patents cover its use to treat the cancer accompanying vitamins (2021).
Although, Alimta, the patent of Eli Lilly and Company has expired in January 2017 at the States and expired in Japan and major European countries in December 2015.
The expiration of Alimta helped other key players to gain regulatory approval to make generic versions of Pemetrexed. They are expected to release during the prediction period. The generic version’s launch will be at a low price. It is expected to increase adoption of this drug. In turn, pemetrexed market growth will be driven over a forecast period.
In July 2018, the German Federal Patent Court announced their German division of European patent EP 1 313 508 for the previously patented drug, Alimta. Following the German Federal Patent Court, STADAPHARM GmbH launched Pemetrexed STADA the generic version of the drug in Europe.
Additionally, Eli Lilly and Company dedicated themselves to many research and development to expand Alimta’s indication and generate enormous revenue benefits.